Keyphrases
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
100%
Chimeric Antigen Receptor T-cell Therapy
84%
Chimeric Antigen Receptor T Cells (CAR-T)
66%
Non-relapse Mortality
42%
Acute Myeloid Leukemia
42%
Large B-cell Lymphoma
35%
Acute Leukemia
31%
Overall Survival
30%
Marrow Transplantation
28%
Leukemia Patients
25%
Relapsed or Refractory
23%
European Society
23%
Anti-CD19 chimeric Antigen Receptor T Cells
22%
CD19 chimeric Antigen Receptor T Cells
21%
Confidence Interval
19%
Transplantation
18%
Cytokine Release Syndrome
18%
Graft-versus-host Disease (GvHD)
17%
Hematopoietic Stem Cell Transplantation
16%
Hazard Ratio
16%
Progression-free Survival
16%
Fludarabine
16%
Immune Effector Cell-associated Neurotoxicity Syndrome (ICANS)
15%
CD19
14%
Aggressive B-cell Lymphoma
14%
Point-of-care
13%
Comorbidity
13%
Tisagenlecleucel
12%
Conditioning Regimen
12%
Lymphoma
12%
Machine Learning
12%
Axicabtagene Ciloleucel
11%
Mortality Prediction
10%
Cell Therapy
10%
Machine Learning Algorithms
10%
Hematotoxicity
10%
Acute Lymphoblastic Leukemia
10%
Working Party
10%
Cell-to-cell
10%
Diffuse Large B-cell Lymphoma (DLBCL)
10%
Complete Remission
10%
High Risk
10%
Umbilical Cord Blood Transplantation
9%
Meta-analysis
9%
Systematic Meta-analysis
9%
Lactate Dehydrogenase
9%
Risk Factors
9%
Leukemia-free Survival
9%
Hematopoietic Cell Transplantation
9%
FMS-like Tyrosine Kinase 3 (FLT3)
9%
Medicine and Dentistry
Chimeric Antigen Receptor T-Cell Immunotherapy
78%
Chimeric Antigen Receptor T-Cell
58%
Acute Myeloid Leukemia
39%
Large-Cell Lymphoma
36%
Diseases
35%
Allogeneic Hematopoietic Stem Cell Transplantation
33%
Overall Survival
32%
Acute Leukemia
21%
Conditioning
21%
Effector Cell
19%
Progression Free Survival
18%
Cytokine Release Syndrome
18%
B-Cell Lymphoma
17%
Neoplasm
17%
Cell Transplantation
16%
Hematopoietic Cell
16%
Hazard Ratio
16%
Allogeneic Stem Cell Transplantation
16%
Non-Relapse Mortality
15%
Toxicity and Intoxication
15%
Non-Hodgkin Lymphoma
13%
Comorbidity
13%
Hematopoietic Stem Cell Transplantation
13%
Systematic Review
13%
Meta-Analysis
13%
Cell Therapy
12%
Acute Lymphoblastic Leukemia
12%
Biological Marker
11%
Infusion
11%
Lactate Dehydrogenase
10%
Leukemia
10%
Axicabtagene Ciloleucel
9%
Cord Blood
9%
Adverse Event
9%
Multiple Myeloma
9%
Cumulative Incidence
9%
Risk Stratification
9%
Fludarabine
8%
Hematologic Malignancy
8%
Chimeric Antigen Receptor
8%
Neurotoxicity
8%
Diffuse Large B-Cell Lymphoma
8%
Scoring System
7%
Cardiovascular System
7%
FMS-Like Tyrosine Kinase 3
7%
Stem Cell Therapy
6%
Odds Ratio
6%
Cord Blood Stem Cell Transplantation
6%
Survival Prediction
6%
Hematology
6%
Immunology and Microbiology
B Cell
39%
Chimeric Antigen Receptor T-Cell
38%
Myeloid
38%
Hematopoietic Cell
32%
Cell Transplantation
31%
Overall Survival
29%
Chimeric Antigen Receptor T-Cell Therapy
29%
Allogeneic Hematopoietic Stem Cell Transplantation
28%
Conditioning
28%
CD19
23%
Comorbidity
21%
Allogeneic Stem Cell Transplantation
21%
Effector Cell
15%
Graft-Versus-Host Disease
14%
Hematopoietic Stem Cell Transplantation
13%
Microbiome
11%
Acute Graft Versus Host Disease
11%
Microflora
10%
Stem Cell Transplantation
10%
Cytokine Release Syndrome
10%
Allograft
9%
Immunotherapy
8%
Progression Free Survival
7%
T Cell
7%
Data Mining
7%
Umbilical Cord Blood
6%
Survival Prediction
6%
Cord Blood Stem Cell Transplantation
6%
Feces microflora
6%
Kidney Function
6%
Bone Marrow Transplantation
6%
Multiple Myeloma
6%
Immune Reconstitution
6%
Cytotoxicity
5%
Albumin
5%
Methotrexate
5%
Metabolic Tumor Volume
5%
